NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT07222384

CompletedPhase 3

Sponsor: BioNTech SE

Conditions: COVID-19, SARS-COV-2 Infection

Interventions: BNT162b2 (2025/2026 formulation)

Countries: United States, Puerto Rico

The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation). This study is seeking participants 5 through 11 years of age who: * have at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19, * and are medically stable. All participants in this study will receive 1 vaccine dose given in the muscle of their arm of a BNT162b2 (2025/2026 formulation) vaccine which targets the COVID-19 virus, specifically the strain selected for the 2025-2026 COVID-19 viral respiratory season. Participants will take part in this study for about 6 months and will need to visit the clinical study site at least 2 times.

Eligibility overview

Sex: ALL

Age: 5 Years to 11 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

* Children 5 through 11 years of age at their first appointment.
* Children with at least 1 underlying stable medical condition that increases their risk of severe COVID-19, as listed in the protocol.

Key Exclusion Criteria:

* Children who have had confirmed COVID-19 within the last 5 months (150 days).
* Children who have received a COVID-19 vaccine, either as part of a research study or an approved vaccine, within the last 5 months (150 days).
* Children who have received a 2025-2026 seasonal COVID-19 vaccination.
* Children with a history of myocarditis or pericarditis.
* Children with a previous or current diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C)
* Children with a medical condition wherein they would be considered for a second dose of COVID-19 vaccine to protect against risk of severe COVID-19 based on standard of care.

Refer to the study contact for further eligibility details.
Locations (29)
  • Palo Alto, California, United States
  • San Diego, California, United States
  • Homestead, Florida, United States
  • Miami, Florida, United States
  • Miami, Florida, United States
  • Miami Lakes, Florida, United States
  • Orlando, Florida, United States
  • St. Petersburg, Florida, United States
  • Ammon, Idaho, United States
  • Oak Brook, Illinois, United States
  • Bardstown, Kentucky, United States
  • Bingham Farms, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Rochester, New York, United States
  • Cincinnati, Ohio, United States
  • Dayton, Ohio, United States
  • South Euclid, Ohio, United States
  • North Charleston, South Carolina, United States
  • Houston, Texas, United States
  • Plano, Texas, United States
  • San Antonio, Texas, United States
  • Stephenville, Texas, United States
  • Layton, Utah, United States
  • Salt Lake City, Utah, United States
  • Salt Lake City, Utah, United States
  • Richmond, Virginia, United States
  • Richmond, Virginia, United States
  • Guayama, Puerto RICO, Puerto Rico
  • Ponce, Puerto RICO, Puerto Rico